Health
Weight Watchers Expands Med+ With Access to New Ozempic® pill (semaglutide)
The addition of Ozempic® pill will give Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for adults living with type 2 diabetesNEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, announced that it will begin offering access to Novo Nordisk’s now available Ozempic® pill (semaglutide) through its Med+ offering and affiliated medical groups. The addition will give members a once-d
About this update from Ww International, Inc.
[{"type":"image","alt":"WW International Inc.","displaySize":"","headline":null,"caption":"WW International Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/6a866065e6a3540f87dba185bc3de450"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZjpyQzAEt23gyRo3rYOuNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3/https://media.zenfs.com/en/globenewswire.com/6a866065e6a3540f87dba185bc3de450","width":300,"height":55}},"lazy":false},{"type":"text","content":"The addition of Ozempic® pill will give Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for adults living with type 2 diabetes","length":144,"tagName":"p"},{"type":"text","content":"NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, announced that it will begin offering access to Novo Nordisk’s now available Ozempic® pill (semaglutide) through its Med+ offering and affiliated medical groups. The addition will give members a once-daily GLP-1 option for adults living with type 2 diabetes, further expanding Weight Watchers’ growing portfolio of oral GLP-1 treatments available through a clinically supported program designed to help members succeed.","length":579,"tagName":"p"},{"type":"text","content":"Novo Nordisk first introduced Ozempic® in the U.S. as an injectable GLP-1 for adults with type 2 diabetes, and the brand has since become one of the most widely recognized names in the category. The Ozempic® pill builds on that foundation, offering a once-daily semaglutide option for adults with type 2 diabetes. With widespread insurance coverage of Ozempic, many eligible members can leverage their pharmacy benefits to make monthly prescription costs as low as $25. Weight Watchers supports members as they navigate prior authorization and utilization management requirements in order to help them find the best option whether that be insurance or cash pay.","length":661,"tagName":"p"},{"type":"text","content":"“For adults living with type 2 diabetes, finding comprehensive support is extremely important, including clinical guidance, appropriate medication, insurance navigation and day-to-day tools” said Jon Volkmann, Chief Operations Officer at Weight Watchers. “With the addition of Ozempic® pill to our ...